Goldman Sachs 47th Annual Global Healthcare Conference 2026
Logotype for Sionna Therapeutics Inc

Sionna Therapeutics (SION) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Sionna Therapeutics Inc

Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

10 Jun, 2026

Key data milestones and study design

  • Two major data readouts are expected in summer 2026: phase II-A proof-of-concept for 719 NBD1 stabilizer as an add-on to Trikafta, and phase I healthy volunteer data for dual combinations involving 451 NBD1 stabilizer with galicaftor or SION-109.

  • The phase II-A study targets a 10 mmol/L sweat chloride improvement, considered clinically meaningful and expected to translate into a 3% FEV1 improvement.

  • The dual combination phase I study will assess safety, tolerability, PK/exposure, and efficacy potential to select the optimal combination for advancement.

  • Strategic decisions post-data will include whether to advance the add-on, the dual combination, or both, depending on data and capital availability.

  • Patient selection for the phase II-A study focuses on those stable on Trikafta with typical responses, aiming for a dynamic range to test NBD1's added benefit.

Clinical and strategic goals

  • Achieving a 10 mmol/L sweat chloride reduction is the efficacy bar, set by community consensus as clinically meaningful and superior to current standards.

  • Both add-on and dual combination programs aim for at least a 10 mmol/L improvement, with the expectation of corresponding FEV1 gains.

  • Dose-ranging studies will follow positive proof-of-concept, maintaining low doses for safety and efficacy, and expanding to both Trikafta and Alyftrek backgrounds.

  • The CFHBE assay is central for predicting clinical efficacy and will be validated if the 10 mmol/L target is met.

  • Future studies may broaden eligibility to include patients with sweat chloride already in the normal range, but initial focus is on those above 30 mmol/L where unmet need is greatest.

Translational and regulatory considerations

  • Strong correlation between sweat chloride reduction and FEV1 improvement underpins the clinical strategy; 10 mmol/L is the threshold where this correlation strengthens.

  • The phase II-A study is powered for sweat chloride, but future pivotal studies will include FEV1 as a registration endpoint.

  • The CFHBE assay's predictive value is considered applicable to broader F508del mutation groups, supporting future expansion.

  • Safety and efficacy data from the dual combination phase I study will guide which combination advances, with both PK and assay data informing the decision.

  • The ultimate goal is to move more patients into the functionally cured range (<30 mmol/L), addressing the largest unmet need in CF.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more